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ABSTRACT 
 
We studied how lagged linear regression can be used to detect the physiologic effects of 
drugs from data in the electronic health record (EHR). We systematically examined the 
effect of methodological variations ((i) time series construction, (ii) temporal 
parameterization, (iii) intra-subject normalization, (iv) differencing (lagged rates of 
change achieved by taking differences between consecutive measurements), (v) 
explanatory variables, and (vi) regression models) on performance of lagged linear 
methods in this context. We generated two gold standards (one knowledge-base derived, 
one expert-curated) for expected pairwise relationships between 7 drugs and 4 labs, and 
evaluated how the 64 unique combinations of methodological perturbations reproduce the 
gold standards. Our 28 cohorts included patients in the Columbia University Medical 
Center/NewYork-Presbyterian Hospital clinical database, and ranged from 2,820 to 
79,514 patients with between 8 and 209 average time points per patient. The most 
accurate methods achieved AUROC of 0.794 for knowledge-base derived gold standard 
(95%CI [0.741, 0.847]) and 0.705 for expert-curated gold standard (95% CI [0.629, 
0.781]). We observed a mean AUROC of 0.633 (95%CI [0.610, 0.657], expert-curated 
gold standard) across all methods that re-parameterize time according to sequence and 
use either a joint autoregressive model with time-series differencing or an independent 
lag model without differencing. The complement of this set of methods achieved a mean 
AUROC close to 0.5, indicating the importance of these choices. We conclude that time-
series analysis of EHR data will likely rely on some of the beneficial pre-processing and 
modeling methodologies identified, and will certainly benefit from continued careful 
analysis of methodological perturbations. This study found that methodological 
variations, such as pre-processing and representations, have a large effect on results, 
exposing the importance of thoroughly evaluating these components when comparing 
machine-learning methods.  
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INTRODUCTION 
 
Widespread adoption of electronic health records (EHRs) over the past 30 years has 
created a rich resource of observational health data, and research communities continue 
to dedicate themselves to leveraging these data to improve clinical care and knowledge 
[1]. EHR-based observational research enables new discoveries that are nearly impossible 
to achieve using traditional experimental methods, and encourages collaborative, open 
science [2]. However, in order to properly leverage EHR data in observational studies, we 
must address the special properties of EHR data by adapting and re-inventing existing 
statistical methods. Here we formulate how to use lagged linear vector regression with 
EHR data, using interactions between medication administration and laboratory 
measurements as our clinical context. 
 
Using EHR data to tackle the identification and characterization of the physiologic effects 
of drugs is a substantial challenge. Although most drugs have known mechanisms of 
intended action, the full diversity of their myriad effects on biological function is poorly 
understood and impractical to study experimentally. Such an understanding is important 
in the context of adverse effects, where drugs induce unexpectedly harmful 
consequences, as well as for uncovering beneficial effects not detected in small, 
controlled clinical trials.  
 
There exist data-driven solutions for studying drugs and their physiologic effects, but 
challenges remain for uncovering their true complexity. Traditional epidemiological 
approaches are most successful for identifying relatively simple trends (e.g. does 
condition X occur after the first administration of drug Y), and progress has been made in 
automatically detecting adverse drug effects [3] using structured clinical databases [4], 
clinical notes [5], [6], and online health forums [7]. Recent work has focused on scaling 
these methods to massive data sets [8] and incorporating all available drug and outcome 
data. Yet finer temporal structure is often desired in order to better understand and predict 
physiologic treatment responses.  
 
Computational methods exist for uncovering detailed temporal relationships between 
drugs and outcomes in EHR data, and recent advances have been made in machine-
learning approaches to phenotyping [9], [10], pattern discovery [11]–[13], temporal 
abstraction over intervals [14], and dynamic Bayesian networks [15]. However, these 
advances typically highlight one or two approaches at a time, and do not rigorously 
justify or study methodological decisions that may be inconsequential or vital to a 
method’s success. In addition, many of these approaches rely on assumptions of 
stationarity that are frequently broken by clinical data [16], [17], or do not account for 
health care process effects.  
 
Hripcsak et al. [18], [19] have demonstrated that time-series methods applied to EHR 
data can identify meaningful, high-fidelity [20] trends that relate drugs and physiologic 
processes. However, standard time-series analysis tools rely on assumptions like 
stationarity and, to a lesser extent, regular sampling frequencies, which are generally 
absent from EHR. We have shown that temporal re-parameterizations can overcome non-
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stationarity, intra-patient normalization can filter out inter-patient effects, and adding 
contextual variables can address health care process effects [21]–[24]. We nevertheless 
lack an understanding of how such specific modeling choices—performed alone or in 
combination—impact inference quality and predictive performance within a lagged linear 
paradigm for analyzing EHR data. 
 
We consider six important steps in time-series modeling of EHR data, and apply two 
specific perturbations to each of the following: (i) time series construction [21], [22], (ii) 
temporal parameterization [23], (iii) intra-subject normalization [21], [22], (iv) 
differencing (lagged rates of change achieved by taking differences between consecutive 
measurements) [24], (v) explanatory variables [24], and (vi) regression models. 
 
Here, we systematically evaluate these methodological perturbations in a combinatorial 
set of 7 drug and 4 lab conditions, and compute a bootstrapped estimate of predictive 
performance with respect to gold standard expectations for each of the 28 pair-wise 
relationships under each of 64 (26) methodological variations. In this way, we probe for 
modeling choices that provide statistically meaningful improvements to detecting 
physiologic drug effects. Furthermore, we obtain a more reliable estimate for the ability 
of well-tuned lagged linear methods to predict physiologic drug effects. 
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MATERIALS AND METHODS 
 
Cohort Criteria 
The 30-year-old clinical data warehouse at NewYork-Presbyterian Hospital, which 
contains electronic health records for over 5 million patients, was used to examine 
pairwise relationships between drug order records and laboratory measurements. We 
selected 7 medications, amphotericin B, simvastatin, warfarin, spironolactone, ibuprofen, 
furosemide, allopurinol and 4 blood laboratory measurements, total creatine kinase, 
creatinine, potassium, hemoglobin, resulting in 28 drug-lab pairwise analyses 
(descriptions are listed in Supplementary Table 2). For each drug-lab pair we identified a 
cohort of patients that met the following criteria: 1) at least 2 of the laboratory 
measurements of interest on record, 2) at least 1 order for the drug of interest, and 3) 
more than 30 combined data points between laboratory measurements of interest and total 
drug orders for any drug. We collected the entire drug-order history, the entire history of 
laboratory measurements of interest, and entire history of inpatient admissions for each 
included patient (for use as optional contextual variables). These selection criteria 
returned between 2,820 and 79,514 patients for the 28 cohorts, with between 8 and 209 
average time points per patient, and between 78,624 and 6,107,601 total time points 
overall. 
Building a time series with clinical data 
We convert binary inputs to continuous values as follows. We constructed a time series 
of drug values by setting all drug-orders of interest to 1, and all orders of other drugs to 0 
[22], and constructed a time series for contextual variables (in this case, inpatient 
admission) by setting the event to 1, and setting a 0 at 24 hours before and after that event 
[24].  
 
Since measurements were sparse and rarely aligned, we interpolated each time series (see 
Figure 1 for a graphical depiction). For every time point where there was a concept (lab, 
drug, or inpatient admission), the values of each other variable at that time point were 
interpolated as the clock-time weighted mean of the preceding and succeeding value of 
each respective variable. Weighting our interpolation by clock-time allows an estimated 
lab value at the time of a drug order to be closest to the nearest lab value, and takes into 
account the trend of the lab near that time. This was performed at each time-point by 
weighting the nearest two bordering concept values according to their temporal distance 
from the interpolated time-point. Ultimately, all concepts, whether from categorical or 
real-valued sources, took on continuous values that were paired at each time point. For a 
more complete description of how we construct a multivariate time series from clinical 
data, see our previous work [22], [24]. 
 
Methodological variations for lagged linear regression with clinical data 
In order to evaluate time series methods for uncovering physiologic drug effects, we 
focused on lagged linear regression and performed 64 (26) perturbations of the standard 
methodology. The data we use are nonstandard, biased by the health care process, non-
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stationary, irregularly measured, and missing not at random, requiring methodological 
explorations to understand how to cope with irregularities of EHR data [23], [25]–[29]. 
We consider temporal parameterization, time series window construction, intra-subject 
normalization, differencing, inclusion of other variables (e.g. related to health care 
process), and choices in how regression models are computed.  
 
Temporal parameterization 
Previous studies have shown that indexing a clinical time series by its sequence order can 
have significant advantages over traditional clock-time [23]. To test this, we indexed our 
lagged analysis with respect to both real-time and sequence-time. Clock-time was 
converted to sequence-time by setting all time intervals between interpolated, pre-
processed values to unit 1 length, making all times ordered integers with no missing 
times. For further details on their implementation, see our previous descriptions [23], 
[24]. 
 
Binning and windowing 
In signal processing, window functions are often used to extract a smoothed or filtered 
segment of a time series near a particular time point. They are typically non-negative and 
smooth over a finite interval; examples include a constant over a rectangle, a triangle, and 
a Gaussian window. The right choice of window function can remove bias from a signal, 
and can improve results of cross-correlation analysis. However, choosing appropriate 
windows is challenging and problem-dependent, and improper choices can lead to 
spurious signals, aliasing, and other spectral leakage pathologies [30]–[33]. 
 
We hypothesize a particular type of bias that we introduce in our timeline construction 
methodology, and attempt to remove it with a simple window function, a maximum 
function over a 24hr width on the drug time series, which we refer to as “binning”. The 
heuristics we have used previously [22] cause drug signals to diminish when a drug of 
interest is consistently ordered between two other drugs. Ideally, the drug timeline should 
retain mass for as long as a patient is consistently taking a drug. We attempted to remove 
this bias by setting all drugs within 12 hours of the drug of interest to 1. It should be clear 
that this process is equivalent to applying a fixed-width window equipped with the max-
function.  
 
Regression Models 
We considered lags from 1-30 days when using real-time, and 1-30 indices when using 
sequence time. We studied two variations of lagged linear regression—univariate (i.e. 
lags estimated one at a time, independently) and multivariable (i.e. lags estimated 
jointly). Independent, univariate estimation provides a simple model similar to lagged 
correlation that separately relates each lagged time-point of each lagged variable to the 
target response variable; joint, multivariable estimation is an autoregression (specifically, 
an ARX model) and computes each lagged coefficient conditional on the other estimates, 
balancing the shared information across lags and thus bringing out more subtle details of 
each lag. First, we considered independent estimation of lagged drug coefficients, 𝛽𝜏, 
from the following model, where 𝑦𝑡 is the lab value (i.e., the outcome of interest) at time 
𝑡, 𝑥𝑡 is the drug value at time 𝑡, and 𝜏 is the lag time (for 𝜏 = 1: 30): 
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𝑦𝑡 = 𝑐𝜏 + 𝛽𝜏𝑥𝑡−𝜏 + 𝜀𝜏 
 
Second, we considered joint autoregressive estimation of lagged drug coefficients, 𝛽𝜏, by 
the following form (L=30): 
 
𝑦𝑡 = 𝑐 + ∑ 𝛽𝜏𝑥𝑡−𝜏
𝐿
𝜏=1
+ ∑ 𝛼𝜏𝑦𝑡−𝜏
𝐿
𝜏=1
+ 𝜀 
 
This form generalizes to an arbitrary number of other lagged explanatory variables, 𝑢𝑖 
(which can include 𝑦), as: 
𝑦𝑡 = 𝑐 + ∑ 𝛽𝜏𝑥𝑡−𝜏
𝐿
𝜏=1
+ ∑ ∑ 𝜔𝜏
𝑖 𝑢𝑡−𝜏
𝑖
𝐿
𝜏=1
𝑁
𝑖=1
+ 𝜀 
 
Differencing 
In time series analysis, pre-processing steps, like taking differences between consecutive 
measurements, are often performed to de-correlate lagged variables [34]. More formally, 
a differencing operator can be applied to resolve non-stationarity that results from a unit 
root in the characteristic equation of an autoregressive stochastic process—the presence 
of a unit root can be identified with statistical tests, like Dickey-Fuller [35], and removed 
by iterative differencing [36]. When unit roots remain, ordinary least squares estimation 
of autoregression coefficients has been shown to fail [37] and non-stationarity persists. 
The simplest example is the case of a random walk, in which each position is highly 
correlated with the previous positions. By taking the differences between consecutive 
steps of a random walk, these correlations are removed and the statistics of the signal can 
be more easily recovered. Similar effects can be seen in clinical data, where treatments 
often drive physiologic change. Levine et al. [24] demonstrated that taking differences is 
an important step in multivariable lagged regression with clinical data; here, we tested the 
value of differencing in additional clinical and methodological contexts. 
 
Intra-patient normalization 
Previous work demonstrated that intra-patient normalization is an important step when 
extracting correct physiologic drug effects using lagged correlation [22]. In order to 
investigate the importance of removing inter-patient effects in different methodological 
contexts, we included the option to normalize each patient’s time series by subtracting 
their mean and dividing by their standard deviation. More sophisticated schemes for 
approaching this problem exist (e.g. Box Cox transform [38] or other power transforms), 
but we wished to first examine a simpler method. It is also important to note that the 
univariate lagged regression coefficient (i.e. AR-1) on normalized (zero mean, unit 
variance) time series is identical to the coefficient from lagged correlation. Thus, as 
various pre-processing and analytic steps are combined, the resulting method often 
devolves into a specially named sub-class of methods. 
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Including context variables 
In order to account for health care process effects and biases, we often wish to include 
potential confounding variables in the model. Levine et al. [24] found that including 
inpatient admission events as autoregressive variables in a multivariable multi-lag model 
(i.e. vector autoregression [34], [39]) attenuated some confounded physiologic signals. 
We evaluated the same approach here, and introduced the context variable 𝑧 to correct 
lagged drug coefficients, 𝛽𝜏: 
 
𝑦𝑡 = 𝑐 + ∑ 𝛽𝜏𝑥𝑡−𝜏
𝐿
𝜏=1
+ ∑ 𝛼𝜏𝑦𝑡−𝜏
𝐿
𝜏=1
+ ∑ 𝛾𝜏𝑧𝑡−𝜏
𝐿
𝜏=1
+ 𝜀 
 
Gold Standard Creation 
In order to evaluate computationally determined interactions between each drug-lab pair, 
we created two gold standards for whether a given drug is expected to increase, decrease, 
or have no effect on a given lab: 1) a knowledge-base derived gold standard that was 
created by synthesizing existing medical literature and knowledge bases—this represents 
information that could, in theory, be obtained automatically, and 2) a clinical expert 
curated gold standard, for which the knowledge-base derived gold standard was 
reviewed and edited by a clinical expert. In table 1, we indicate whether a given drug is 
expected to increase, decrease, or have no effect on a given lab (denoted as 1, -1, 0, 
respectively), according to the two gold standards (68% total agreement, Cohen’s 
Kappa=0.53, 95% CI [0.27-0.78]). 
 
Literature search for expected physiologic drug effects 
For each drug-lab pair, an author (ML) searched PubMed for articles using the drug and 
lab as keywords, along with terms “increase”, “decrease”, and “association”. The authors 
selected articles that reported quantitative information about associations and causations 
between the two entities within their abstracts. The author then read these articles and 
determined whether their reported associations between the drug and lab of interest 
should be expected to generalize to a large EHR database (e.g., a study of cancer patients 
would not be included). 
 
LAERTES knowledge base queries for expected physiologic drug effects 
The LAERTES (Large-scale Adverse Effects Related to Treatment Evidence 
Standardization) [40] knowledge-base was developed as part of the Observational Health 
Data Sciences and Informatics initiative to record existing pharmacosurveillance 
knowledge that could be compared to new empirical evidence. It draws from package 
inserts, Food and Drug Administration databases, and also the literature. LAERTES was 
queried for associations between side effects associated with the 4 lab measurements 
(muscle weakness and rhabdomyolysis for creatine kinase, renal impairment for 
creatinine, hyperkalemia and hypokalemia for potassium, and anemia for hemoglobin) 
and each of the 7 drugs.  
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Knowledge-base derived gold standard—combining results from literature search and 
knowledge base 
Resulting directional associations from LAERTES were taken in union with the 
directional associations from our literature search. When one search method yielded no 
associations, and the other did, we took the association, rather than the null result (except 
in the case of ibuprofen and total creatine kinase, for which we rejected LAERTES’s 
positive result). When multiple results were present in the LAERTES results, we selected 
those that matched results in the literature—this occurred twice, for spironolactone’s 
effect on potassium and ibuprofen’s effect on potassium. Together, these data formed the 
knowledge-base derived gold standard. 
 
Expert-curated gold standard 
A clinical expert (GH) subsequently curated the knowledge-base derived gold standard, 
and modified 9 of its 28 expected associations. The expert modified the directionality 
only twice (i.e. -1 to +1), where he believed that diuretic-induced anemia was less likely 
to be present than rises in hemoglobin due to diuretic-induced fluid loss. The other seven 
modifications removed expected effects in the knowledge-base derived gold standard (i.e. 
changed +1 or -1 to 0), which the expert judged sufficiently rare to be missing from a 
database of the size of ours. 
 
Evaluating accuracy of lagged regressions 
 
We evaluated the predictive accuracy of each tested method and the associated 
uncertainty by performing a layered bootstrap resampling over patient cohorts [41]. 
Figure 2 provides a schematic for the experimental protocol. 
 
Estimating variance of lagged drug coefficients 
We empirically computed estimates of variance for the lagged drug coefficients, 𝛽𝜏, 
using a bootstrap estimate of variance. For each drug-lab cohort, we sampled patients 
with replacement to create 200 bootstrapped samples, and ran all 64 regressions for each 
of these 200 samples from the drug-lab cohort. We estimated the variance of 𝛽𝜏 using the 
variance of these samples, and subsequently determined empirical 95% confidence 
intervals of 𝛽𝜏 ([𝛽𝜏 − 1.96𝜎, 𝛽𝜏 − 1.96𝜎], where 𝜎 is the standard deviation of the 
samples of 𝛽𝜏). 
 
Classifying lagged drug coefficient profiles 
We are ultimately interested in the trajectory of 𝛽𝜏 as they vary over 𝜏, and write 𝜷 =
 {𝛽𝜏}𝜏=1
30 . In order to perform a first-order evaluation of lagged drug coefficients 
trajectories, we first converted them to the format of the gold standards (increase, 
decrease, or no effect). We classified 𝜷 as increasing (+1) if at least 15 consecutive 
coefficients were all greater than zero within 95% confidence interval, decreasing (-1) if 
at least 15 consecutive coefficients were all less than zero within 95% confidence 
interval, and neither (0) otherwise. We selected 15 as the threshold because it is half-the 
number of total estimated coefficients, making it the smallest threshold that can ensure 
there will be only one directional designation (we did not want a trajectory of 𝜷 to be 
classified as both increasing and decreasing). 
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Computing predictive performance of lagged regressions with respect to gold standards 
For each of the 64 method combinations, we evaluated classifications of the 28 gold 
standard drug-lab effects by estimating a Receiver Operating Characteristic (ROC) curve, 
and reported the area under ROC (AUROC) separately for the two gold standards. Recall 
that AUROC is a common evaluation metric for binary classification models, and is equal 
to the expected probability that the model will rank a randomly chosen positive event 
above a randomly chosen negative one. 
 Given our ranked classifications (-1,0,1), we evaluated sensitivity and specificity of each 
method’s ability to perform binary discrimination across two thresholds, -0.5 and 0.5, 
which provided two points for an ROC curve. We computed AUROC using simple 
trapezoidal integration. 
 
Estimating variance of AUROC for each methodological variation 
In order to estimate the variance of each method’s AUROC, we leveraged the previously 
performed bootstrapped regressions. For each of the 200 previously computed estimates 
of 𝜷 for each drug-lab pair, we created a new classification using a confidence interval 
with fixed variance (previously computed) that was centered at that particular 
bootstrapped estimate of 𝜷. 
 
We thus obtained 200 independent samples of 𝜷. We classified these, and subsequently 
arrived at 200 independent, identically applied samples of AUROC for each 
methodological variation, which were used to statistically compare performance of 
different methods. 
 
Comparing predictive performance of lagged regression methods 
We want to compare disjoint classes of methods; for example, we want to compare all 
methods that use sequence time against all methods that use real time, and ask whether 
sequence time or real time offers an average performance benefit. In order to perform 
such comparisons, we report the average difference between AUROCs and the 95% 
Confidence Intervals (CIs) of this difference for both gold standards. Concretely, we 
compared two disjoint groups of methods by computing the difference between each 
group’s mean AUROC. We then estimated the 95% CI of this difference using the 
variance of the pairwise differences between each group’s 200 mean sampled AUROCs. 
This results in a determination of whether one disjoint group of methods is better or 
worse than another, within a 95% CI, and enables queries like “overall, is it better to use 
sequence time or real time?” or “overall, is it better to use sequence time with or without 
normalization?”. 
 
We performed these comparisons systematically to arrive at a final set of statistically 
significant methodological variations. First, we evaluated the impact of each variation 
across all other variations, i.e. marginal impact; for example, we compared all methods 
that use normalization against all methods that do not. Then we evaluated the impact of 
each variation given a variation of another variable; for example, we compared all 
methods that use normalization and sequence time against all methods that use 
normalization and real time. We also compared sequences of 3 variations. This allowed 
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us to evaluate the impact of methods, both alone and in combination. We report 
methodological variations that are influential alone and in combination with others, along 
with the magnitude of their marginal impact on AUROC. 
 
Summary 
In order to evaluate and compare methodological variations of lagged linear regressions 
for determining physiologic drug effects from clinical time series, we 1) identify patient 
cohorts for each drug-lab pair of interest, 2) report the predictive performance of each 
method with respect to two gold standards, and 3) draw statistically meaningful 
comparisons between classes of methods to demonstrate important modeling steps that 
ought to be taken either alone or in combination to achieve desired results. 
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RESULTS 
 
Illustrating example of importance of methodological variations of lagged linear 
regression for assessing physiologic drug effects 
In order to illustrate the importance of variations in methodology for analysis of clinical 
time series, we examined some possible inferences of the relationships between 
amphotericin B and levels of potassium and creatinine. Our knowledge-base derived gold 
standard and clinical expert agreed that amphotericin B should be expected to raise 
creatinine levels and lower potassium levels.  
 
Figure 3 shows the resulting inferences when varying three aspects of the computation 
(temporal parameterization, differencing, and regression models) and fixing the other 
three aspects (normalization, no additional context variable, and no binning). Figure 3a 
shows that the expected trends are accurately reconstructed with statistical significance 
when using sequence time, differences, and a joint AR model. Figures 3b and 3c show 
that no significant association can be found when switching to real-time or not using 
differences. However, Fig 3d shows that multiple changes to the successful method in Fig 
3a (using an independent lag model and not using differences) can obtain expected 
trends, albeit with less significance for creatinine (blue). Results from these 
methodological combinations for all 28 drug-lab pairs are shown in Supplementary 
Figures 1-7. 
 
Combinatorial evaluation of lagged regression assessments of physiologic drug effects 
under methodological variations 
In order to thoroughly understand the impact of methodological choices in this context, 
we evaluated all 64 combinations of methods with respect to the two gold standards 
(knowledge-base derived, and expert-curated). 
 
Our main results are shown in Figure 4. We report each method’s AUROC and an 
estimate of the AUROC variance for both gold standards; we rank the results by 
descending expert-curated AUROC, and indicate the vector of method pairings for each 
row in the plot. These results are also enumerated explicitly in Supplementary Table 1. 
 
We first point out that, surprisingly, the majority of method combinations had AUROC of 
0.5, indicating performance no better than chance. This implies that the choice of 
methods, combinations of methods, and even the data representation—differences versus 
raw values—is very important. Furthermore, while the two gold standards differed 
significantly according to Table 1, they agreed fairly well on which combinations were 
better than chance. The superior performance of some combinations does not appear to be 
artifact. 
 
We observe that there is a concentration of methods using sequence time at the top of the 
plot, suggesting that sequence time is a beneficial choice independent of other methods. 
We can also observe patterns that relate differencing with model choice—in particular, 
we note that of our four possible combinations of differencing and model, only two of 
these (differences with joint estimation and no differences with independent estimation) 
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ever yield AUROC above 0.5. This suggests an interaction between these two choices, 
which we subsequently interrogate quantitatively. 
 
The best method, according to the expert-curated gold standard used sequence time, 
normalization, differencing, a joint AR model, no binning, and no additional context 
variable (AUROC = 0.705, 95%CI [0.629, 0.781]). According to the knowledge-base 
derived gold standard, the best method also used sequence time, normalization, and no 
additional context variable, but did not use differencing, used an independent lag model, 
and used binning (AUROC = 0.794, 95%CI [0.741, 0.847]). 
 
Comparing predictive performance between lagged regression methods 
We test for statistically significant differences between marginal effects of different 
method variations. We observe that choosing sequence time instead of real time is the 
only single methodological choice that both gold standards agree has a statistically 
significant effect. For the knowledge-base derived gold standard, sequence time yields a 
0.049 (95%CI [0.035, 0.063]) marginal AUROC improvement over real time; for the 
expert-curated gold standard, the marginal improvement is 0.050 (95%CI [0.038, 0.062]). 
 
In addition, we examined combinations of method choices, and found a consistent, 
statistically significant indication that a joint AR model is better with differences than 
without (0.062 marginal AUROC improvement with 95%CI [0.045, 0.079] for 
knowledge-base derived gold standard, 0.074 marginal AUROC improvement with 
95%CI [0.053, 0.094] for expert-curated gold standard), and that an independent lagged 
model is worse with differences than without (0.083 marginal AUROC reduction with 
95%CI [-0.100, -0.065] for knowledge-base derived gold standard, 0.094 marginal 
AUROC reduction  with 95%CI [-0.114, -0.075] for expert-curated gold standard). We 
also evaluated the converse statements (e.g. when using differences, is joint AR or 
independent lag model significantly better), and found similar associations.  
 
We further compared the two preferred pairs, and found that while the independent lag 
model without differences slightly outperformed the joint AR model with differences 
overall (0.021 marginal AUROC improvement for both gold standards), these changes 
were not statistically significant (95%CI [-0.046,0.004] for knowledge-base derived gold 
standard, 95% CI [-0.049,0.008] for expert-curated gold standard). However, the 
opposite, albeit statistically insignificant, effect was observed when comparing these 
methods only in the context of the clearly preferred sequence time. 
 
We ultimately found that once a choice of sequence time and either of the preferred pairs 
of differencing and modeling (i.e. no differences with independent lag model or 
differences with joint AR model) was made, no additional choices (binning, context 
variables, normalization) provided marginal improvement to AUROC with statistical 
significance. We observe a mean AUROC of 0.633 (95%CI [0.610, 0.657]) for expert-
curated gold standard (and 0.622 mean AUROC with 95%CI [0.603, 0.641] for 
knowledge-base derived gold standard) across methods that use sequence time and one of 
the preferred difference-model pairs, whereas the complement of this set of methods 
achieves a mean AUROC close to 0.5 (0.512 with 95%CI [0.506, 0.517] for clinically 
 14 
curated-gold standard; 0.507 with 95%CI [0.503, 0.512] for knowledge-base derived gold 
standard). In this way, we demonstrate that temporal parameterization, time series 
differencing, and regression-type are important choices that must be selected in concert to 
achieve optimal predictive performance. 
 
Comparing evaluations from two gold standards 
The gold standards differed on 32% of cases (Cohen’s Unweighted Kappa=0.53, 95% CI 
[0.27-0.78]; Cohen’s Linear Weighted (ordinal) Kappa=0.54, 95% CI [0.11-0.97]). In 
two cases, the knowledge-base derived gold standard reported diuretics as possibly 
causing anemia, thus lowering hemoglobin, without accounting for potential diuretic fluid 
loss and resultant rise in hemoglobin. This represents a disconnect between the condition 
(anemia) and the observed entity (hemoglobin), which was noted by the expert. In other 
cases, a potential side effect was judged to be sufficiently rare that it should be missing 
from a database of the size of ours. 
 
The effect of the difference in gold standards can be seen in Figure 4 and Figure 5. Figure 
5 shows that the AUROCs for each methodological variation are correlated across the 
two gold standards (Pearson correlation coefficient 0.759, 95%CI [0.631, 0.847), but that 
substantial differences exist. Figure 4 shows that each gold standard would rank 
individual methods differently; nevertheless, major conclusions of the study, such as the 
superiority of using sequence time and the dependencies between differencing and 
regression-type, are upheld by both gold standards. 
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DISCUSSION 
 
Here we study how lagged linear regressions, a simple, robust, commonly used class of 
methods, can be tuned to efficiently extract drugs’ temporal effects on patient physiology 
from EHR data. Data in the EHR present a variety of challenges (low, erratic 
measurement frequency, high noise, and non-stationarity), making time-series analysis 
highly non-trivial and requiring careful pre-processing and re-parameterization. We 
evaluated combinations of pre-processing, modeling, and temporal parameterization steps 
in order to understand how to better cope with challenges in extracting temporal 
information from EHR data. We used 64 of these methodological perturbations to 
analyze 28 drug-lab pairs, and evaluated the results against two gold standards. 
 
We found that the correct combination of regression type (independent lag or joint 
autoregressive) and differencing was essential—independent lag models cannot be used 
with differencing, whereas the joint AR model must be used differencing. Furthermore, 
we found a large significant improvement (for expert-curated gold standard, 0.05 average 
AUROC increase, 95%CI [0.038, 0.062]) when re-indexing time according to the 
sequence of events. These selections created high-performing methods, and the top 
methods achieved AUROC of over 0.7 (for knowledge-base derived gold standard, best 
AUROC = 0.794, 95%CI [0.741, 0.847]; for expert-curated gold standard, best AUROC 
= 0.705, 95% CI [0.629, 0.781]).  
 
We also found that the regressions were robust to our choices of normalization, binning, 
and context variable inclusions. While these choices were statistically unimportant, in 
aggregate, among our cohorts, their impact could become more noticeable when testing 
different hypotheses or when using different data. Moreover, we selected one simple 
form for each of these variations, and it is likely that more targeted formulations will 
have greater effects. 
 
Benefits of multiple gold standards 
Gold standards often vary, but by using several gold standards, researchers can—
formally or informally—assess their evaluations’ sensitivities to the gold standard. If only 
one gold standard is used, then there is no way to characterize the dependency of 
conclusions on that particular gold standard. In our case, results were similar but not 
identical for the two gold standards, indicating that our findings are not mere artifacts of 
the gold standard. It is important to note that our gold standards were not completely 
independent, as one author created the knowledge-base derived gold standard, and the 
clinical expert modified it according to clinical and informatics knowledge. 
 
Reflections on important methodological steps 
We found that decomposing the overall modeling process into smaller, discrete methods 
allowed us to systematically interrogate the effect of each choice. However, it is also 
instructive to note that many of the combinations of methods are in fact equivalent to 
established methodologies. For example, the joint autoregressive model is very similar to 
Granger causality, and the independent lag model is analogous to lagged correlation 
analysis up to normalization. Both of these modeling methods, combined with any 
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windowing function, fall under similar classes of statistical spectral analysis methods and 
econometrics [34], [36], [42]–[44]. 
 
Our previous studies have reported improved performance of lagged methods on EHR 
data when using sequence time [23], [24], and have investigated the mechanics of these 
phenomena [16], [17], [23]. We maintain the hypothesis that sequence time removes non-
stationarity by leveraging the fact that clinicians sample at rates proportional to patient 
variability [23], [45], but feel that this hypothesis, while implied, has yet to have been 
explicitly proven. Lagged regression methods rely on assumptions of weak stationarity, 
and their performance improves when data are pre-processed to remove temporal swings 
in mean and variance. There exist methods like autoregressive moving average models 
that can cope with certain relatively benign non-stationarity effects, such as a slowly and 
continuously varying mean, but these models are likely unable to resolve clinical non-
stationarity effects that are combined with data missing non-randomly (e.g., correlated 
with health). Such EHR-data-specific pathologies were the original motivation for even 
attempting sequence time-based methods. 
 
Non-stationarity in EHR data may partly manifest in unit roots of the characteristic 
equation of the autoregressive stochastic process, causing failure of ordinary least squares 
estimation, and ought to be explicitly tested in the future using the augmented Dickey-
Fuller test [34], [35]. While we optionally applied a differencing operator once to our 
clinical time series, we did not test for the presence of unit roots. Future work may 
benefit from iteratively applying a difference operator and re-testing with a statistical test, 
like augmented Dickey-Fuller, until unit roots are removed, as is the strategy of the Box-
Jenkins modeling approach [36].  
 
Differencing is a well-known method [34] for reducing correlation between lagged 
variables in time-series analysis, and Levine et al. [24] provided anecdotal evidence of its 
benefit for lagged linear analysis of drug and lab data from the EHR. For this reason, we 
expected it to improve results across all methods. We were surprised to learn that 
differencing corrupted the performance of the independent lag model. We recognize, 
however, that there is a tradeoff between sharing uncorrelated information across 
variables and adding noise to any particular variable. In the case of the independent lag 
model, we correlate with one variable at a time, effectively losing all of the upside of 
differencing. Because the joint autoregressive model holds some advantages over the 
independent lag model (it is easier and more intuitive to add additional explanatory 
variables to the joint model), differencing clearly has an important role to play in 
temporal analysis of EHR data. Incorporating rates of change must typically be done 
intentionally within any machine learning framework, including deep learning, either by 
pre-processing the features or by choosing model structures that learn temporal feature 
representations as linear combinations of neighboring sequential elements. 
 
Opportunities for revealing finer temporal structure in EHR data 
It is also important to note that lagged coefficients from these analyses contain 
information far more rich than the evaluated classifications (increasing, none, or 
decreasing physiologic responses). The trajectories of lagged coefficients (as seen in 
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Figure 2, c.f. Figures 6-8 in [21], c.f. Figure 2 in [22]) can shed light on temporal 
dynamics and important time scales of the physiologic and/or health care process, rather 
than merely indicate the presence of an effect. We originally wanted to also evaluate 
these methods for their ability to detect finer temporal associations, but challenges remain 
for creating a reliable gold standard upon which to base validations of more complex 
insights, such as the rate or magnitude of a drug’s physiologic effect (trustworthy 
quantitative information of this type does not exist for most cases). With sufficient 
validation, properly tuned lagged linear methods may eventually become useful for 
discovering novel associations in EHR data. 
 
Implications for comparing machine learning methods 
Most of the tested method combinations failed (AUROC=0.5), indicating that these 
choices are critically important. We observe that, for the same machine-learning 
algorithm, differences in preprocessing and experimental setup result in a range of 
AUROC from 0.5 to 0.8. Therefore, the choice of an overall algorithm (regression, 
support vector machines, neural networks, decision trees, etc.) is just one factor that 
could affect results, and researchers need to be mindful of this not only when performing 
experimental comparisons of algorithms, but also when presenting the results of these 
comparisons. While sophisticated machine-learning techniques aid learning of data 
representation, the structure for these models is still often selected based on certain 
hypotheses about how the data might be best represented. Our results suggest that data 
representations, either pre-processed or learned, should look like sequence time, and, 
most likely, contain information about the differences between successive measurements 
and normalize values across patients in the data set. Preprocessing conditions may have 
different effects on different methods, so a variety of these conditions ought to be 
rigorously tested, compared, and reported. The combination of pre-processing 
methodology and choice of gold standards could have large effects on machine learning 
evaluations, and it is likely that confidence intervals normally reported in machine 
learning studies fail to include the uncertainty related to these choices. 
 
Implications for reproducibility of observational studies 
Our evaluation pipeline is an important part of reproducible observational research, 
allowing researchers to quantify the impact of the various modeling choices made 
throughout the research process. Thorough comparisons across wider ranges of methods 
and source data are critical for advancing our ability to trust what we can learn from the 
EHR. The Observational Health Data Science and Informatics (OHDSI) consortium 
provides a common data model and a research community dedicated to such reproducible 
and generalizable advancements, and we aim to expand our pipeline into an OHDSI-
compatible, open-source repository. 
 
How to choose the right method 
We have demonstrated the value of rigorous, systematic perturbations to chosen methods, 
and we encourage readers to perform similar evaluations in their own research contexts. 
However, we also hope that our results are somewhat generalizable to time-series 
analyses of medical data. We have found sequence time to provide a large, significant 
performance boon, and strongly recommend that researchers in similar domains consider 
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re-indexing their time-series according to sequences. For lagged linear analysis, we 
recommend using either a simple independent lag model (without differencing) or a joint 
autoregressive model with differencing (recall that differencing corrupted the signals 
from the independent lag model). In general, we recommend performing differencing in 
accordance with results from statistical tests of unit root presence, like augmented 
Dickey-Fuller [34]. While we identified no statistical difference between the joint AR 
model with differencing and the independent lag model without differencing, qualitative 
assessment (e.g. see supplementary figures 1-7) suggests that the joint AR model 
provides finer resolution of temporal dynamics of physiologic process. In addition, even 
when the joint AR and independent lag models return the same drug-effect 
classifications, the joint AR model appears to be more robustly representative of the 
classification (e.g. supplementary figure 1, where it more clearly depicts that 
amphotericin B has no effect on total creatine kinase). These qualitative inspections cause 
us to favor the joint autoregressive model with differencing. Intra-patient normalization 
had no statistically significant effect in our cohort, but we recommend its continued 
usage, because a) it has been shown to improve performance in similar studies [22], and 
b) it did not create any disadvantage in our current study. We did not observe any useful 
effect from our experimental choice of windowing, and recommend readers select none 
or constant window functions as opposed our experimental choice. However, we 
encourage researchers to more thoroughly investigate appropriate windowing functions 
for EHR data, and insist that this be done in combination with other potential 
methodological choices, as there may be unexpected method-dependent dependencies. 
By studying the impact of methodological variations alone and in concert with each 
other, we can improve model performance and help make research results more 
generalizable and implementable for researchers. 
 
LIMITATIONS 
This study was performed at a single academic medical center, and its findings may not 
generalize to different sources of medical record data. The gold standards are subject to 
existing, accessible knowledge. The selected method for classifying lagged coefficients 
was not studied rigorously, and may possess unforeseen biases. 
 
CONCLUSIONS 
We used lagged linear methods to detect physiologic drug effects in EHR data. We used 
two clinical gold standards and a bootstrap methodology to evaluate the reliance of 
lagged methods on combinations of methodological perturbations. We observed 
important statistically significant improvements from particular combinations of temporal 
re-parameterization, time-series differencing, and regression model choice. We expect 
that these steps will play an important role in revealing fine temporal structure from EHR 
data, and we recognize the overarching importance of systematic comparison of machine 
learning methods under a broad range of pre-processing scenarios. 
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TABLES 
 
Drug Laboratory 
Measurement 
Knowledge-
base derived 
gold standard 
Expert-curated 
gold standard 
Allopurinol Total Creatine Kinase 1 0 
Allopurinol Creatinine 1 1 
Allopurinol Potassium 0 0 
Allopurinol Hemoglobin -1 0 
Amphotericin B Total Creatine Kinase 0 0 
Amphotericin B Creatinine 1 1 
Amphotericin B Potassium -1 -1 
Amphotericin B Hemoglobin -1 -1 
Furosemide Total Creatine Kinase 0 0 
Furosemide Creatinine 1 1 
Furosemide Potassium -1 -1 
Furosemide Hemoglobin -1 1 
Ibuprofen Total Creatine Kinase 0 0 
Ibuprofen Creatinine 1 0 
Ibuprofen Potassium 1 0 
Ibuprofen Hemoglobin -1 -1 
Simvastatin Total Creatine Kinase 1 1 
Simvastatin Creatinine 1 0 
Simvastatin Potassium 1 0 
Simvastatin Hemoglobin -1 0 
Spironolactone Total Creatine Kinase 0 0 
Spironolactone Creatinine 1 1 
Spironolactone Potassium 1 1 
Spironolactone Hemoglobin -1 1 
Warfarin Total Creatine Kinase 0 0 
Warfarin Creatinine 0 0 
Warfarin Potassium 0 0 
Warfarin Hemoglobin -1 -1 
Table 1. Clinical gold standards for expected drug effects. 
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FIGURES 
 
Fig 1. Timeline Construction. We performed a linear temporal interpolation in order to 
align sparse, asynchronous measurements and events. For every time point where there 
was a value (lab, drug concept, or context (i.e. inpatient admission)), the values of each 
other variable at that time point were interpolated as the clock-time weighted mean of the 
preceding and succeeding value of each respective variable. 
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Figure 2. Experimental Design Overview 
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Figure 3. Signal quality is noticeably affected by combinations of methodological choices, 
especially temporal parameterizations, differencing, and lag model type; here we vary these 3 
dimensions, and fix the remaining 3 using intra-patient normalization, no binning, and no 
additional context variables. Here, we expect Amphotericin B to increase Creatinine (hence, blue 
should be significantly above zero) and Amphotericin B to decrease Potassium (hence, red should 
be significantly below zero). The figures demonstrate that sequence-time is often a necessary, 
singular choice: figure 3a, which uses sequence time, produces the expected result, whereas 
figure 3b shows a non-significant noise pattern; the methods used in these figures differ only by 
their treatment of temporal parameterization. The figures also demonstrate that methods must be 
combined carefully—figure 3a combines differencing with the joint AR model, and produces 
expected patterns, whereas figure 3c uses an identical method, but omits differencing, and 
produces a non-significant noise pattern. However, pairing the independent lag model without 
differencing appears to reconstruct the signal, albeit with less significance than fig 3a. 
 
  
a) 
b) 
c) d) 
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Figure 4. 
This figure displays AUROC confidence intervals for each of 26 methodological combinations. 
AUROCs are ordered from top-to-bottom in descending order of AUROC from the expert-
curated gold standard. The heatmap on the left indicates the presence (tan) or absence (blue) of 
each of the 6 method variables for each plotted AUROC. For example, the top AUROC method 
(according to the clinically-curated gold standard) used sequence-time, no binning, intra-patient 
normalization, differencing, no additional context variable, and a joint AR model. Note that these 
results are enumerated explicitly in Supplementary Table 1. 
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Figure 5.  
Here we plot the correlation (Pearson correlation coefficient 0.759, p=3.7e-13) between AUROCs 
computed using clinically curated and knowledge-base derived gold standards. Error bars for 
each AUROC couple are 95% Confidence Intervals computed using a bootstrap resampling. We 
observe that the two gold standards, despite significant disagreements (Table 1), ultimately 
provide evaluations with reasonable similarity. This result instills a confidence in both gold 
standards that could not be achieved with a single gold standard. 
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SUPPLEMENTARY MATERIALS 
 
Supplementary Table 1 
Time Binned Normalized Difference Context 
variables 
Estimation Expert-
curated 
Gold 
Standard 
AUROC  
Expert-
curated 
Gold 
Standard 
AUROC 
SD 
Knowledge
-base 
derived 
Gold 
Standard 
AUROC 
Knowledge
-base 
derived 
Gold 
Standard 
AUROC 
SD 
Sequence No Yes Yes Yes Joint AR 0.705 0.04 0.627 0.03 
Sequence No Yes Yes No Joint AR 0.705 0.04 0.627 0.03 
Sequence Yes Yes No Yes Independent 0.654 0.02 0.728 0.02 
Sequence Yes No No No Independent 0.654 0.03 0.524 0.01 
Sequence No Yes No No Independent 0.651 0.02 0.718 0.03 
Sequence Yes No Yes No Joint AR 0.646 0.04 0.691 0.04 
Sequence No No Yes No Joint AR 0.640 0.04 0.585 0.04 
Sequence No No Yes Yes Joint AR 0.640 0.04 0.585 0.03 
Sequence Yes Yes Yes No Joint AR 0.637 0.03 0.649 0.03 
Real Yes Yes No No Independent 0.626 0.03 0.664 0.03 
Sequence Yes Yes No No Independent 0.621 0.03 0.794 0.03 
Sequence Yes No No Yes Independent 0.613 0.03 0.500 0.01 
Sequence No Yes No Yes Independent 0.610 0.02 0.702 0.03 
Sequence Yes No Yes Yes Joint AR 0.602 0.03 0.587 0.03 
Sequence Yes Yes Yes Yes Joint AR 0.601 0.04 0.639 0.03 
Real Yes Yes No Yes Independent 0.595 0.04 0.662 0.03 
Real No No No No Independent 0.593 0.04 0.500 0.02 
Real No No No Yes Independent 0.593 0.04 0.500 0.02 
Sequence No No No No Independent 0.575 0.02 0.500 0.01 
Sequence No No No Yes Independent 0.575 0.03 0.500 0.00 
Real Yes No No No Independent 0.574 0.03 0.500 0.02 
Real Yes No No Yes Independent 0.574 0.03 0.500 0.02 
Real No Yes No No Independent 0.500 0.02 0.516 0.04 
Real No Yes No Yes Independent 0.500 0.02 0.516 0.04 
Sequence No Yes No No Joint AR 0.500 0.00 0.500 0.00 
Sequence No No No No Joint AR 0.500 0.00 0.500 0.00 
Sequence Yes Yes No No Joint AR 0.500 0.00 0.500 0.00 
Sequence Yes No No No Joint AR 0.500 0.00 0.500 0.00 
Real No Yes Yes No Joint AR 0.500 0.00 0.500 0.00 
Real No Yes No No Joint AR 0.500 0.00 0.500 0.00 
Real No No Yes No Joint AR 0.500 0.00 0.500 0.00 
Real No No No No Joint AR 0.500 0.00 0.500 0.00 
Real Yes Yes Yes No Joint AR 0.500 0.01 0.500 0.00 
Real Yes Yes No No Joint AR 0.500 0.00 0.500 0.00 
Real Yes No Yes No Joint AR 0.500 0.01 0.500 0.01 
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Real Yes No No No Joint AR 0.500 0.00 0.500 0.00 
Sequence No Yes No Yes Joint AR 0.500 0.00 0.500 0.00 
Sequence No No No Yes Joint AR 0.500 0.00 0.500 0.00 
Sequence Yes Yes No Yes Joint AR 0.500 0.00 0.500 0.00 
Sequence Yes No No Yes Joint AR 0.500 0.00 0.500 0.00 
Real No Yes Yes Yes Joint AR 0.500 0.00 0.500 0.00 
Real No Yes No Yes Joint AR 0.500 0.00 0.500 0.00 
Real No No Yes Yes Joint AR 0.500 0.00 0.500 0.00 
Real No No No Yes Joint AR 0.500 0.00 0.500 0.00 
Real Yes Yes Yes Yes Joint AR 0.500 0.00 0.500 0.00 
Real Yes Yes No Yes Joint AR 0.500 0.00 0.500 0.00 
Real Yes No Yes Yes Joint AR 0.500 0.00 0.500 0.00 
Real Yes No No Yes Joint AR 0.500 0.00 0.500 0.00 
Sequence No Yes Yes No Independent 0.500 0.00 0.500 0.00 
Sequence No No Yes No Independent 0.500 0.00 0.500 0.00 
Sequence Yes Yes Yes No Independent 0.500 0.00 0.500 0.00 
Sequence Yes No Yes No Independent 0.500 0.00 0.500 0.00 
Real No Yes Yes No Independent 0.500 0.00 0.500 0.00 
Real No No Yes No Independent 0.500 0.00 0.500 0.00 
Real Yes Yes Yes No Independent 0.500 0.01 0.500 0.01 
Real Yes No Yes No Independent 0.500 0.02 0.500 0.01 
Sequence No Yes Yes Yes Independent 0.500 0.00 0.500 0.00 
Sequence No No Yes Yes Independent 0.500 0.00 0.500 0.00 
Sequence Yes Yes Yes Yes Independent 0.500 0.00 0.500 0.00 
Sequence Yes No Yes Yes Independent 0.500 0.00 0.500 0.00 
Real No Yes Yes Yes Independent 0.500 0.00 0.500 0.00 
Real No No Yes Yes Independent 0.500 0.00 0.500 0.00 
Real Yes Yes Yes Yes Independent 0.500 0.00 0.500 0.00 
Real Yes No Yes Yes Independent 0.500 0.00 0.500 0.00 
Supplementary Table 1 lists the evaluation metrics (AUC with standard deviation with 
respect to each gold standard) for each of the 64 methodological combinations. 
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Supplementary Table 2  
 
Allopurinol 
CPMC DRUG: ALLOPURINOL 100 MG TAB 
CPMC DRUG: ALLOPURINOL 300 MG TAB 
CPMC DRUG: UD ALLOPURINOL 100 MG TAB 
CPMC DRUG: UD ALLOPURINOL 300 MG TAB 
ALLOPURINOL 
ALLOPURINOL PREPARATIONS 
ALLOPURINOL 100 MG TABLET 
ALLOPURINOL 300 MG TABLET 
ALLOPURINOL TABLETS 
CERNER DRUG: ALLOPURINOL TAB 300 MG 
CERNER DRUG: ALLOPURINOL SUSP 5 MG/ML 
CERNER DRUG: ALLOPURINOL TAB 100 MG 
CERNER DRUG: ALLOPURINOL INJ 500 MG 
CERNER DRUG: ALLOPURINOL PO SUSP 20 MG/ML EXT 
ALLOPURINOL SUSP 5 MG/ML 
ALLOPURINOL INJ 500 MG 
ALLOPURINOL 20 MG/ML PO SUSPENSION 
CERNER DRUG: ALLOPURINOL IV SYR 6 MG/ML D5W 
CERNER DRUG: ALLOPURINOL IV SYR 6 MG/ML NS 
 
Amphotericin B 
CPMC DRUG: FUNGIZONE 50 MG VIAL 
AMPHOTERICIN B 
AMPHOTERICIN B PREPARATIONS 
CPMC DRUG: AMPHOTERICIN B 50MG FOR AEROSO 
CPMC DRUG: AMPHOTERICIN B (FUNGIZONE) 
CPMC DRUG: AMPHOTERICIN 3% CREAM 20 GM 
CPMC DRUG: .AMPHOTERICIN B (FUNGIZONE) 
CPMC DRUG: AMPHOTERICIN B LIPID 5MG/ML IN 
AMPHOTERICIN B 3 % 
AMPHOTERICIN B 0 IDA VIAL 
AMPHOTERICIN B 5 MG/ML 
CPMC DRUG: FUNGIZONE OR SUS 100MG/ML 24ML 
CPMC DRUG: .AMPHOTERICIN B LIPID 5MG/ML 
CERNER DRUG: AMPHOTERICIN B LIPOSOME IVPB *R* 
CERNER DRUG: AMPHOTERICIN B SUSP 100 MG/ML 24 ML 
CERNER DRUG: AMPHOTERICIN B LIPID 5 MG/ML INJ *NF* 
CERNER DRUG: AMPHOTERICIN B LIPID 2 MG/ML INJ SYR *NF* 
CERNER DRUG: AMPHOTERICIN B INJ 50 MG 
CERNER DRUG: AMPHOTERICIN B APPROVAL 
CERNER DRUG: AMPHOTERICIN B - 0.1 MG/ML INJ SYR *R* 
CERNER DRUG: AMPHOTERICIN B EXT OPHT 5 MCG/0.1 ML INJ 0.3 ML 
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CERNER DRUG: AMPHOTERICIN B LIPID APPROVAL 
CERNER DRUG: AMPHOTERICIN B LIPOSOME APPROVAL 
CERNER DRUG: AMPHOTERICIN B LIPOSOME *APPROVAL* 
CERNER DRUG: AMPHOTERICIN B LIPOSOME APPROVAL (2) 
AMPHOTERICIN B SUSP 100 MG/ML 
AMPHOTERICIN B 1 MG/ML 
AMPHOTERICIN B 2 MG/ML 
AMPHOTERICIN B 0.1 MG/ML 
AMPHOTERICIN B 0.25 MG/ML 
AMPHOTERICIN B LIPID PREPARATIONS 
AMPHOTERICIN B LIPOSOME PREPARATIONS 
CERNER DRUG: AMPHOTERICIN B LIPID NEBULIZER 5 MG/ML *NF* 
CERNER DRUG: AMPHO B LIPOSOME IV SY 2 MG/ML D5W 
CERNER DRUG: AMPHOTERICIN B SOLN 0.1 MG/ML 10ML 
CERNER DRUG: AMPHOTERICIN B - 0.5 MG/ML INJ SYR *R* 
CERNER DRUG: AMPHO B DEOXY OPH DROP 1.5MG/ML 10M 
CERNER DRUG: AMPHO B DEOXY 0.1 MG/ML CNS *R* 
CERNER DRUG: AMPHOTERICIN B INTRATHECAL APPROVAL 
CERNER DRUG: AMPHOTERICIN B LIPOSOMAL 50 MG INJ *R* 
CERNER DRUG: AMPHOTERICIN B LIPOSOMAL NEBULIZER 25 MG/6 ML 
SOLN 
 
Furosemide 
FUROSEMIDE PREPARATIONS 
FUROSEMIDE 
CPMC DRUG: FUROSEMIDE 20 MG TAB 
CPMC DRUG: FUROSEMIDE 40 MG TAB 
CPMC DRUG: LASIX 10 MG/ML 10 ML AMP 
CPMC DRUG: LASIX 10 MG/ML 2 ML AMP 
CPMC DRUG: LASIX SOLN 10 MG/ML 60 ML 
CPMC DRUG: UD FUROSEMIDE 20 MG TAB 
CPMC DRUG: UD FUROSEMIDE 40 MG TAB 
CPMC DRUG: LASIX 10 MG/ML 2 ML INJ 
CPMC DRUG: FUROSEMIDE 10 MG/ML SOL 
CPMC DRUG: FUROSEMIDE 10 MG/ML SOL 60 ML 
CPMC DRUG: FUROSEMIDE 10 MG/ML 2 ML INJ 
CPMC DRUG: FUROSEMIDE 100 MG/10 ML INJ 
CPMC DRUG: .LASIX 10 MG/ML 2 ML INJ 
CPMC DRUG: .FUROSEMIDE 20 MG TAB 
OPERATING ROOM MEDICATION: FUROSEMIDE 
FUROSEMIDE 80MG TABLET 
FUROSEMIDE 10 MG/ML 
FUROSEMIDE 20 MG TABLET 
FUROSEMIDE 40 MG TABLET 
FUROSEMIDE TABLETS 
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CPMC DRUG: UD LASIX 40 MG TAB 
CERNER DRUG: FUROSEMIDE TAB 40 MG 
CERNER DRUG: FUROSEMIDE SOLN 10 MG/ML 120 ML B 
CERNER DRUG: FUROSEMIDE ELIX 40 MG/5 ML DU 
CERNER DRUG: FUROSEMIDE INJ 10 MG/ML 4 ML 
CERNER DRUG: FUROSEMIDE SOLN 10 MG/ML 60 ML B 
CERNER DRUG: FUROSEMIDE NEB *IND* 2 ML 
CERNER DRUG: FUROSEMIDE TAB 20 MG 
CERNER DRUG: FUROSEMIDE INJ 10 MG/ML 2 ML 
CERNER DRUG: FUROSEMIDE IVPB COMPOUND 
CERNER DRUG: FUROSEMIDE IV SY 5 MG/ML NS 
CERNER DRUG: FUROSEMIDE IV SY 10 MG/ML 
CERNER DRUG: FUROSEMIDE INJ 10 MG/ML 10 ML 
CERNER DRUG: FUROSEMIDE INFUSION 10 MG/ML 
CERNER DRUG: FUROSEMIDE TAB 80 MG 
CERNER DRUG: FUROSEMIDE PO SOLN 10 MG/ML EXT 
FUROSEMIDE ELIX 8 MG/ML 
FUROSEMIDE IV 5 MG/ML 
FUROSEMIDE 80 MG TABLET 
CERNER DRUG: FUROSEMIDE IV SY 1 MG/ML NS 
CERNER DRUG: FUROSEMIDE 1 MG/ML SYRINGE 
CERNER DRUG: FUROSEMIDE 5 MG/ML SYRINGE 
CERNER DRUG: FUROSEMIDE 0.5 MG/ML SYRINGE 
CERNER DRUG: FUROSEMIDE 10 MG/ML SYRINGE 
CERNER DRUG: FUROSEMIDE 10 MG/ML INJ SYR 
CERNER DRUG: FUROSEMIDE 100 MG/100 ML NS 
CERNER DRUG: FUROSEMIDE 40 MG/4 ML SOLN UD 
 
Simvastatin 
SIMVASTATIN PREPARATIONS 
CPMC DRUG: SIMVASTATIN W/LACTOSE 10MG TAB 
CPMC DRUG: UD SIMVASTATIN 5 MG TAB 
CPMC DRUG: UD SIMVASTATIN 10 MG TAB 
CPMC DRUG: SIMVASTATIN 20 MG TAB 
CPMC DRUG: SIMVASTATIN 40 MG TAB 
SIMVASTATIN TABLETS 
SIMVASTATIN 10 MG TABLET 
SIMVASTATIN 20 MG TABLET 
SIMVASTATIN 40 MG TABLET 
SIMVASTATIN 5 MG TABLET 
SIMVASTATIN 
CERNER DRUG: SIMVASTATIN TAB 20 MG 
CERNER DRUG: SIMVASTATIN TAB 40 MG 
CERNER DRUG: SIMVASTATIN TAB 10 MG 
CERNER DRUG: SIMVASTATIN TAB 5 MG 
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SIMVASTATIN 80MG TABLET 
CERNER DRUG: SIMVASTATIN TAB 80 MG 
 
Spironolactone 
CPMC DRUG: ALDACTONE 25 MG TAB 
CPMC DRUG: UD ALDACTONE 25 MG TAB 
SPIRONOLACTONE 
SPIRONOLACTONE PREPARATIONS 
CPMC DRUG: SPIRONOLACTONE 25 MG TAB 
CPMC DRUG: UD SPIRONOLACTONE 25 MG TAB 
CPMC DRUG: SPIRONOLACTONE SUS 5 MG/ML 
SPIRONOLACTONE 5 MG/ML 
SPIRONOLACTONE 25 MG TABLET 
SPIRONOLACTONE TABLETS 
SPIRONOLACTONE 100 MG TABLET 
SPIRONOLACTONE 50 MG TABLET 
CERNER DRUG: SPIRONOLACTONE PO SUSP 5 MG/ML EXT 
CERNER DRUG: SPIRONOLACTONE-HCTZ *NF* 25 MG 
CERNER DRUG: SPIRONOLACTONE TAB 25 MG 
CERNER DRUG: SPIRONOLACTONE TAB 100 MG *NF* 
 
Ibuprofen 
CPMC DRUG: MOTRIN 400 MG TAB 
CPMC DRUG: MOTRIN 600 MG TAB 
CPMC DRUG: UD MOTRIN 400 MG TAB 
CPMC DRUG: UD MOTRIN 600 MG TAB 
IBUPROFEN 
IBUPROFEN PREPARATIONS 
CPMC DRUG: PEDIAPROFEN 100 MG/5 ML 120 ML 
CPMC DRUG: UD IBUPROFEN 600 MG TAB 
CPMC DRUG: UD IBUPROFEN 400 MG TAB 
IBUPROFEN 100 MG/ML 
IBUPROFEN 400 MG TABLET 
IBUPROFEN 600 MG TABLET 
IBUPROFEN 800 MG TABLET 
IBUPROFEN TABLETS 
IBUPROFEN 100 MG TABLET 
IBUPROFEN 200 MG TABLET 
IBUPROFEN 300 MG TABLET 
IBUPROFEN CHEWABLE TABLETS 
IBUPROFEN 100 MG CHEWABLE TABLET 
IBUPROFEN 50 MG CHEWABLE TABLET 
IBUPROFEN CAPSULES 
IBUPROFEN 200 MG CAPSULE 
CPMC DRUG: ADVIL CAPLETS 
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CERNER DRUG: IBUPROFEN TAB 400 MG 
CERNER DRUG: IBUPROFEN TAB 200 MG 
CERNER DRUG: IBUPROFEN TAB 600 MG 
CERNER DRUG: IBUPROFEN SUSP 100 MG/5 ML 120ML B 
CERNER DRUG: IBUPROFEN PO SUSP 20 MG/ML EXTEMP 
IBUPROFEN SUSP 20 MG/ML 
CERNER DRUG: IBUPROFEN SUSP 100 MG/5 ML UD 
CERNER DRUG: IBUPROFEN LYSINE INJ 20 MG/2 ML *R* 
IBUPROFEN, LYSINE SALT PREPARATIONS 
LYSINE SALT OF IBUPROFEN 
CERNER DRUG: IBUPROFEN LYSINE IV SY 5 MG/ML D5W 
CERNER ME ORDER: ZZIBUPROFEN (ARUP) 
CERNER ME DTA: IBUPROFEN 
CERNER DRUG: IBUPROFEN INJ 100 MG/ML 8 ML *R* 
CERNER DRUG: IBUPROFEN INJ 100 MG/ML 4 ML *R* 
CERNER DRUG: IBUPROFEN IVPB *R* 
 
Warfarin 
CPMC DRUG: COUMADIN 10 MG TAB 
CPMC DRUG: COUMADIN 2 MG TAB 
CPMC DRUG: COUMADIN 2.5 MG TAB 
CPMC DRUG: COUMADIN 5 MG TAB 
CPMC DRUG: UD COUMADIN 10 MG TAB 
CPMC DRUG: UD COUMADIN 2 MG TAB 
CPMC DRUG: UD COUMADIN 2.5 MG TAB 
CPMC DRUG: UD COUMADIN 5 MG TAB 
CPMC DRUG: COUMADIN 7.5 MG TAB 
CPMC DRUG: UD WARFARIN SOD 1 MG TAB 
CPMC DRUG: UD WARFARIN 2 MG TAB 
WARFARIN 7.5 MG TABLET 
WARFARIN 1 MG TABLET 
WARFARIN 2 MG TABLET 
WARFARIN 2.5 MG TABLET 
WARFARIN 5 MG TABLET 
WARFARIN 10 MG TABLET 
WARFARIN TABLETS 
WARFARIN SODIUM 4 MG TABLET 
CERNER DRUG: WARFARIN TAB 1 MG 
CERNER DRUG: WARFARIN TAB 10 MG *DNO* 
CERNER DRUG: WARFARIN TAB 7.5 MG 
CERNER DRUG: WARFARIN TAB 2 MG 
CERNER DRUG: WARFARIN TAB 2.5 MG 
CERNER DRUG: WARFARIN TAB 5 MG 
CERNER DRUG: WARFARIN TAB 0.5 MG (PRODUCTION) 
WARFARIN 0.5 MG TABLET 
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CERNER DRUG: WARFARIN 3 MG TAB 
WARFARIN PREPARATIONS 
 
Total Creatine Kinase 
SERUM CREATINE KINASE TEST 
SERUM CREATINE PHOSPHOKINASE MEASUREMENT 
SERUM TOTAL CREATINE KINASE TEST 
SERUM CREATINE KINASE MEASUREMENT 2 
SERUM CREATINE KINASE TEST 2 
NEW CHEM20 PLASMA CREATINE KINASE TEST 
CPMC LABORATORY TEST: OLD PLASMA CREATINE PHOSPHOKINASE 
CPMC LABORATORY TEST: CK, TOTAL 
PLASMA TOTAL CREATINE KINASE TEST 
NYH LAB PROCEDURE: CREATINE KINASE 
NYH LAB PROCEDURE: TOTAL CK (CK ISOENEZYME) 
CPMC LABORATORY TEST: SERUM CREATINE KINASE 
CPMC LABORATORY TEST: CREATINE KINASE(ALLEN) 
CPMC LABORATORY TEST: CK,TOTAL 
CPMC LABORATORY TEST: CK TOTAL 
CERNER ME DTA: CREATINE KINASE 
CERNER ME DTA: CK, TOTAL (QUEST 88001232) 
 
Creatinine 
SERUM CREATININE MEASUREMENT 
PRESBYTERIAN PLASMA CREATININE TEST 
ALLEN PLASMA CREATININE MEASUREMENT 
CHEM-7 CREATININE MEASUREMENT 
SERUM CREATININE TESTS 
SERUM CREATININE MEASUREMENT 2 
NEW CHEM-7 PLASMA CREATININE MEASUREMENT 
CPMC LABORATORY TEST: OLD PLASMA CREATININE MEASUREMENT 
CPMC LABORATORY TEST: CREATININE 
NYH LAB PROCEDURE: CREATININE 
NYH LAB PROCEDURE: PRE CREATININE 
NYH LAB PROCEDURE: POST CREATININE 
CPMC LABORATORY TEST: SERUM CREATININE MEASUREMENT 
WHOLE BLOOD CREATININE TESTS 
CPMC LABORATORY TEST: CREATININE, WHOLE BLOOD 
CREATININE MANUALLY ENTERED BY HEALTH PROFESSIONAL 
CPMC LABORATORY TEST: CREATININE WHOLE BLOOD 
CPMC LABORATORY TEST: CREATININE WHOLE BLOOD (ALLEN) 
CERNER ME DTA: CREATININE 
NYH LAB PROCEDURE: CREATININE, W/B 
CPMC LABORATORY TEST: CREATININE  (ISTAT) 
CERNER ME DTA: CREATININE WHOLE BLOOD POC 
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CERNER ME DTA: CREATININE WB 
CERNER ME DTA: CREATININE (QUEST) 
CERNER ME DTA: CREATININE BGV 
CERNER ME DTA: CREATININE BGA 
CERNER ME DTA: CRE WB - EPOC 
CERNER ME DTA: CREATININE (PLASMA) 
INTRAVASCULAR CREATININE TEST 
 
Potassium 
STAT WHOLE BLOOD POTASSIUM ION MEASUREMENT 
PRESBYTERIAN WHOLE BLOOD POTASSIUM ION MEASUREMENT 
SERUM POTASSIUM ION MEASUREMENT 
PRESBYTERIAN PLASMA POTASSIUM ION TEST 
ALLEN PLASMA POTASSIUM ION MEASUREMENT 
ALLEN WHOLE BLOOD POTASSIUM ION MEASUREMENT 
CHEM-7 POTASSIUM ION MEASUREMENT 
WHOLE BLOOD POTASSIUM TESTS 
SERUM POTASSIUM ION TESTS 
SERUM POTASSIUM ION MEASUREMENT 2 
NEW CHEM-7 PLASMA POTASSIUM ION MEASUREMENT 
CPMC LABORATORY TEST: OLD PLASMA POTASSIUM MEASUREMENT 
CPMC LABORATORY TEST: POTASSIUM, WHOLE BLOOD 
CPMC LABORATORY TEST: K WHOLE BLOOD 
CPMC LABORATORY TEST: POTASSIUM(ALLEN) 
OPERATING ROOM MISC LABS: K 
NYH LAB PROCEDURE: POTASSIUM 
NYH LAB PROCEDURE: POTASSIUM, PLASMA 
NYH LAB PROCEDURE: POTASSIUM , W/B 
CPMC LABORATORY TEST: SERUM POTASSIUM MEASUREMENT 
PLASMA POTASSIUM TESTS 
CPMC LABORATORY TEST: POTASSIUM ISTAT 
POTASSIUM MANUALLY ENTERED BY HEALTH PROFESSIONAL 
CPMC LABORATORY TEST: POTASSIUM WHOLE BLOOD 
CPMC LABORATORY TEST: POTASSIUM WHOLE BLOOD (ALLEN) 
CERNER ME DTA: POTASSIUM LEVEL 
CERNER ME DTA: POTASSIUM WHOLE BLOOD POC 
CERNER ME DTA: POTASSIUM WB 
CERNER ME DTA: POTASSIUM PLASMA 
CERNER ME DTA: POTASSIUM W/B - EPOC 
CPMC LABORATORY TEST: POTASSIUM WHOLE BLOOD POC 
CERNER ME DTA: POTASSIUM POC IL 
CERNER ME DTA: POTASSIUM-TOTAL RBC (QUEST) 
CERNER ME DTA: K POST 
INTRAVASCULAR POTASSIUM TEST 
 
 37 
Hemoglobin 
STAT WHOLE BLOOD HEMOGLOBIN MEASUREMENT 
PRESBYTERIAN PATHOLOGY WHOLE BLOOD HEMOGLOBIN 
MEASUREMENT 
PRESBYTERIAN CHEMISTRY WHOLE BLOOD HEMOGLOBIN MEASUREMENT 
ALLEN WHOLE BLOOD HEMOGLOBIN TEST 
ALLEN WHOLE BLOOD HEMOGLOBIN MEASUREMENT 
RESPIRATORY BLOOD HEMOGLOBIN MEASUREMENT 
STAT LABORATORY HEMOGLOBIN MEASUREMENT 
CPMC LABORATORY TEST: HGB(C) 
CPMC LABORATORY TEST: HEMOGLOBIN 
CPMC LABORATORY TEST: HGB 
CPMC LABORATORY TEST: MEASURED HEMOGLOBIN 
CPMC LABORATORY TEST: TOTAL HEMOGLOBIN 
OPERATING ROOM MISC LABS: HGB 
NYH LAB PROCEDURE: TOTAL HEMOGLOBIN 
NYH LAB PROCEDURE: HEMOGLOBIN 
CPMC LABORATORY TEST: HEMOGLOBIN 59947 
NYH LAB PROCEDURE: HEMOGLOBIN W/B 
CPMC LABORATORY TEST: HGB (M) 
CPMC LABORATORY TEST: HGB (M) (ALLEN) 
CPMC LABORATORY TEST: TOTAL HEMOGLOBIN (C) 
CPMC LABORATORY TEST: HEMOGLOBIN, POC 
CERNER ME DTA: HEMOGLOBIN 
CERNER ME DTA: HEMOGLOBIN POC 
CERNER ME DTA: HEMOGLOBIN TOTAL POC 
CERNER ME DTA: HEMOGLOBIN WB 
CERNER ME DTA: TOTAL HGB 
CERNER ME DTA: HEMOGLOBIN W/B - EPOC 
CPMC LABORATORY TEST: HEMOGLOBIN POC 
CERNER ME DTA: TOTAL HGB POC IL (FOR CO-OX) 
CERNER ME DTA: HGB-UNV 
CERNER ME DTA: TOTAL HEMOGLOBIN POC IL 
CERNER ME DTA: HEMOGLOBIN WHOLE BLOOD POC 
CERNER ME DTA: HEMOGLOBIN (ARUP 2011401) 
WHOLE BLOOD HEMOGLOBIN CONCENTRATION TESTS 
Supplementary Table 2 lists the names of all laboratory tests and drug orders extracted 
for the analysis. 
  
 38 
Supplementary Figure 1 
 
Lagged regression results from four different methodological variations are shown here 
for amphotericin B’s effect on creatinine, potassium, total creatine kinase, and 
hemoglobin. Specifically, we show 4 illustrative combinations of temporal 
parameterization, differencing, and model choices; in all figures, intra-patient 
normalization was used, no windowing or binning was performed, and no additional 
context variable was used. 
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Supplementary Figure 2 
 
Lagged regression results from four different methodological variations are shown here 
for simvastatin’s effect on creatinine, potassium, total creatine kinase, and hemoglobin. 
Specifically, we show 4 illustrative combinations of temporal parameterization, 
differencing, and model choices; in all figures, intra-patient normalization was used, no 
windowing or binning was performed, and no additional context variable was used. 
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Supplementary Figure 3 
 
Lagged regression results from four different methodological variations are shown here 
for spironolactone’s effect on creatinine, potassium, total creatine kinase, and 
hemoglobin. Specifically, we show 4 illustrative combinations of temporal 
parameterization, differencing, and model choices; in all figures, intra-patient 
normalization was used, no windowing or binning was performed, and no additional 
context variable was used. 
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Supplementary Figure 4 
 
Lagged regression results from four different methodological variations are shown here 
for warfarin’s effect on creatinine, potassium, total creatine kinase, and hemoglobin. 
Specifically, we show 4 illustrative combinations of temporal parameterization, 
differencing, and model choices; in all figures, intra-patient normalization was used, no 
windowing or binning was performed, and no additional context variable was used. 
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Supplementary Figure 5 
 
Lagged regression results from four different methodological variations are shown here 
for ibuprofen’s effect on creatinine, potassium, total creatine kinase, and hemoglobin. 
Specifically, we show 4 illustrative combinations of temporal parameterization, 
differencing, and model choices; in all figures, intra-patient normalization was used, no 
windowing or binning was performed, and no additional context variable was used. 
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Supplementary Figure 6 
 
Lagged regression results from four different methodological variations are shown here 
for furosemide’s effect on creatinine, potassium, total creatine kinase, and hemoglobin. 
Specifically, we show 4 illustrative combinations of temporal parameterization, 
differencing, and model choices; in all figures, intra-patient normalization was used, no 
windowing or binning was performed, and no additional context variable was used. 
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Supplementary Figure 7 
 
Lagged regression results from four different methodological variations are shown here 
for allopurinol’s effect on creatinine, potassium, total creatine kinase, and hemoglobin. 
Specifically, we show 4 illustrative combinations of temporal parameterization, 
differencing, and model choices; in all figures, intra-patient normalization was used, no 
windowing or binning was performed, and no additional context variable was used. 
 
